ClinicalTrials.gg
Not yet recruitingNCT07015346STARTUpdated Aug 7, 2025

Adhesion and Safety of Rotigexole Compared to Neupro®

An interventional study of Rotigexole 8 mg and Neupro ® 8 mg in Idiopathic Parkinson Disease, sponsored by Eva Pharma. Not yet recruiting. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Eva Pharma · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Planned enrollment
34th of 42
40 · median 123
Started
2025
the only one that year
No phase
Only one
of the 44
Registered
44th of 44
by date
Lead sponsor
1 of 44
Eva Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2025, is the only one with no phase, and was the 44th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now.

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application

Read the detailed description

Study Design: A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application.

Planned Treatment Duration per Subject and Study Duration per Subject:

The overall duration of the study preparation and study conduction is 7 weeks and 5 days (54 days) that are scheduled as follows:

  1. Preparatory Phase of the Study: Patients Screening (2 weeks):

    Patient screening for eligibility will occur over 14 days. During this time, all relevant administrative, demographic data collection, and informed consent will be conducted for eligible patients.

  2. Run-in-Phase (3 weeks):

    • On the first day of the run-in phase, prior to drug administration, comprehensive physical and laboratory re-assessments will be conducted to document the initial patient's systemic status which will be monitored throughout the study to observe any potential systemic alterations for ethical purposes.
    • The transdermal patch Rotigotine (Neupro ®) only will be applied in the run-in phase in a dose taper manner on weekly basis according to the European Medicines Agency (1) and the US FDA (2) recommendations for treating cases of PD. A starting dose of 4 mg/24 h initially, increasing in weekly increments of 2 mg/24 h (based on clinical response and tolerability) to a maximum of 8 mg/24 h; starting dose of 4 mg/24 h in the 1st week will be applied followed by 6 mg/24 h in the 2nd week and finally 8 mg/24 h in the 3rd week.
    • The patch should be applied on clean, dry, healthy skin on the abdomen (tummy), thigh, hip, side, shoulder or upper arm.
    • A Rotigotine transdermal patch necessitates daily replacement as the drug delivery lasts for 24 hours only (3-5). Notably, re-application at the same site should be avoided for 14 days.
    • Comprehensive physical and laboratory assessments will be re-evaluated at the last day of the run-in-phase and prior to the commencement of the following intervention phase.
  3. Intervention Phase of the Study:

    • This phase will last for five days only.
    • At this phase patients will be randomly assigned to sequence of TRTR or RTRT (T=Test=Rotigexole, R=Reference= Neupro ®). Each transdermal patch, either T or R, will be replaced at the same time every 24 hours.
    • Patients will receive accommodation for four nights during the intervention period to assess adhesion. Adhesion assessments will occur at 4, 8, 12 and 24 hours in accordance with FDA guidelines for transdermal patch evaluation.
    • The application of the transdermal patches should be on different sites of the same region "abdomen (tummy), thigh, hip, side, shoulder or upper arm".
    • Subjects must refrain from using topical products on the skin area designated for TDS application due to potential effects on adhesion. Additionally, hair at the application site should be clipped rather than shaved.
    • The alternating transdermal patch should then be applied on the same site of the same region on the contralateral side.
    • During this period, the patient is allowed to practice his or her routine activities without any restrictions in movement.
    • Assessments will be performed just after application and will be repeated at 4, 8, 12 and 24 hours
    • Patch reinforcement such as over-taping should be avoided.
    • At each assessment, photographic documentation of TDS adhesion to the skin must be archived. This documentation serves to corroborate the visual evaluation of adhesion percentages recorded at each time point.
    • At the final assessment of the 2nd transdermal patch application, the patient will be prescribed an alternative medicament (Ramixole) to stabilize the patient's conditions.
  4. Post-intervention Phase:

    • All participants will undergo a comprehensive re-evaluation two weeks post-study to identify any systemic alterations for safety and ethical considerations (one follow-up visit).
    • Any arising adverse systemic conditions in patients will be appropriately managed
03

Conditions studied

  • Idiopathic Parkinson Disease

Browse trials for

Keywords

  • Rotigexole
  • Rotigotine
  • non-inferiority
  • open label
  • multicentric
  • randomized
  • cross-over
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female patients aged ≥30 years at Screening
  2. Diagnosed with idiopathic Parkinson's disease with a Hoehn and Yahr stage of II to III.
  3. Patients who have not received dopamine agonists in the past 30 days or are willing to discontinue current dopamine agonist therapy for the duration of the study
  4. Subjects should have a (MMSE) score of ≥25 at Screening.
  5. Participants who are able to tolerate Rotigotine transdermal patch incremental run-in period for 3 weeks.
  6. Willing to refrain from swimming, bathing or sauna use on assessment days.
  7. Participants should be using a reliable method of (e.g., intrauterine device, barrier methods, condoms) throughout the study and for at least 30 days after the last dose of study medication
  8. Female participants should have a negative pregnancy test at screening, before starting study medication and for at least 30 days after the last dose of study medication
  9. Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with a medical history indicating a Parkinsonian syndrome other than idiopathic PD (e.g., drug-induced, post-stroke)
  2. History of significant skin to adhesives or other transdermal products.
  3. History of or clinical features consistent with atypical parkinsonian syndromes (e.g., multiple system atrophy, progressive supranuclear palsy)
  4. CNS or psychiatric disorders other than idiopathic PD (mild depression or anxiety arising in the context of PD is not exclusionary).
  5. Use of any symptomatic drug for PD other than levodopa, pramipexole, ropinirole, or Rotigotine within 60 days prior to the first dose.
  6. Patients with a history of brain surgery for PD (e.g., pallidotomy, thalamotomy, deep brain stimulation).
  7. Recent exposure to monoamine oxidase type A inhibitors, amphetamines, dopamine-depleting antihypertensive agents, neuroleptics, or antiemetics that block central dopamine activities.
  8. Unstable or cardiovascular disease within the last year prior to screening (e.g., arrhythmias, conduction blocks, congestive heart failure.
  9. Concomitant disease or unstable medical condition within 6 months of screening that could interfere with the study or treatment.
  10. Participant has history of or presence of neuroleptic malignant syndrome at screening as assessed by the investigator.
  11. Participant has a current diagnosis of Epilepsy, has a history of seizures, stroke, or within 1 year prior to screening
  12. Presence of surface antigen (HBsAg) or positive for total hepatitis B core antibody (HbcAb), or positive (HCV) at screening.
  13. Vaccines other than SARS-CoV-2 vaccine within 28 days prior to the first dose or plans to receive vaccines during the study or within 28 days of the last dose.
  14. History of immunodeficiency disease (e.g., ).
  15. Clinically significant abnormalities in laboratory test results at screening, including hepatic and renal panels, complete blood count, chemistry panel, and urinalysis.
  16. Recently unresolved allergies, hypersensitivity, contact dermatitis or an active skin disease.
  17. Participants who have history of alcohol abuse within 6 months before screening as assessed by the investigator.
  18. Pregnant or lactating females
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Test: Rotigexole 8 mg/24 hours transdermal patch

    At the beginning of the intervention phase, patients' randomization will take place to determine the sequence of reference (R) and test (T) administration to either RTRT group or TRTR group. After obtaining all baseline characteristics, once daily patch application of one patch of 8 mg/24 h of Test (T) or Reference (R) over 4 days, i.e. a total of 4 alternating applications with RT sequence or TR sequence will be administered. Each patch remains applied for 24 h and the treatment patches may be directly switched without washout phase.

    Drug: Rotigexole 8 mg

  • Active comparator
    Reference: Neupro® 8 mg/ 24 hours transdermal patch

    At the beginning of the intervention phase, patients' randomization will take place to determine the sequence of reference (R) and test (T) administration to either RTRT group or TRTR group. After obtaining all baseline characteristics, once daily patch application of one patch of 8 mg/24 h of Test (T) or Reference (R) over 4 days, i.e. a total of 4 alternating applications with RT sequence or TR sequence will be administered. Each patch remains applied for 24 h and the treatment patches may be directly switched without washout phase.

    Drug: Neupro ® 8 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The cumulative mean percentage adhesion of the transdermal patch over the 24-hour dosing interval for two treatment periods, compared between Rotigexole (Test) and Neupro® (Reference)

    Using a mixed-effects model adjusted for period and sequence effects, with subject as a random effect

    Time frame: two treatment periods (4 days)

Secondary outcomes

  1. Proportion of participants achieving more than 90% adherence at 4, 8, 12 and 24 hours at each period as assessed by the investigator/designee as per modified EMA scale for adhesion.

    Time frame: two treatment periods (4 days)

  2. Adjusted Mean adherence percentage at each assessment time (4, 8, 12 and 24 hours).

    Time frame: two treatment periods (4 days)

  3. Proportion of participants with a meaningful degree of detachment (more than half of the patch lifting off the skin or falling off) at 4, 8, 12 and 24 hours.

    Time frame: two treatment periods (4 days)

  4. Number of patches that are completely detached at 4, 8, 12 and 24 hours.

    Time frame: two treatment periods (4 days)

  5. Number of participants with cold flow in each treatment period (Cold flow is defined as dark ring formed around the patch).

    Time frame: two treatment periods (4 days)

  6. Number of participants with patch movement/displacement in each treatment period.

    Time frame: two treatment periods (4 days)

  7. Number of participants with patch wrinkling in each treatment period.

    Time frame: two treatment periods (4 days)

  8. Number of participants with patch residue formation in each treatment period (Patch residue formation is assessed at patch application on the release liner and at patch removal on the skin).

    Time frame: two treatment periods (4 days)

  9. % of patients reporting ease or difficulty in patch application and removal.

    Time frame: two treatment periods (4 days)

  10. Frequency of Adhesion-Related Issues: Evaluate the frequency of adhesion-related issues (e.g., patch detachment).

    Time frame: two treatment periods (4 days)

  11. % of patients with reported interference in daily activities due to patch adhesion.

    Time frame: two treatment periods (4 days)

  12. % of patients reporting overall satisfaction with wearing each patch type, measured using a Patch Wear Satisfaction Scale.

    Time frame: two treatment periods (4 days)

  13. The incidence, seriousness and severity of adverse events (AEs) including application site reactions, and discontinuations because of AEs

    Time frame: two treatment periods (4 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Oct 2025, 1 month later.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 1 month is below that.

Counting every sponsor, half of 1,370 studies reached it within 25 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 11, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Oct 15, 2025
CompletionEst.
Oct 30, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015346
Lead sponsor
Eva Pharma
Collaborators
MARC-CRO
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Oct 15, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Aug 7, 2025

Study contacts

Lydia Bahig
Contact
lydia.bahig@marc-eg.org
01225952401
Hatem S Mohammed, Dr.
principal investigator · Al-Manial Specialized Hospital - Cairo University
Ali S Shalash, Dr.
principal investigator · Ain Shams Specialized Hospital - Ain Shams University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion